ABSTRACT
Objective: To study the preliminary pharmacodynamics effect of Shuiludihuang Capsule on rats with type 2 diabetic nephopathy induced by high-fat and sugar diet combined low dose streptozotocin (STZ), and to investigate its mechanism. Methods: Type 2 diabetic nephropathy animal model was established by feeding with high fat and sugar diet combined with low dose of STZ. The FBS, TC, TG, UMA, kidney weight, the hypertrophy index, etc were measured to study its effects of reducing blood glucose and protecting kidney, and its pharmacodynamic effects were expounded by kidney pathological section. The expressions of Angptl4, Desmin and NF-κB in kidney tissues were tested by immunohistochemistry, The expressions of Angptl4 and Desmin in kidney tissues were tested by western blotting, and APN, LEP and Urine Angptl4 were tested by ELISA to probe into its mechanism tentatively. Results: Compared with the model control group, kidney weight, the hypertrophy index, FBG, TC, TG, LEP and the expressions of Angptl4, Desmin and NF-κB in rats of each group (9, 6 mg/kg) were significantly decreased, and body mass, the serum APN level were significantly increased, with significant difference (P < 0.05, P < 0.01). Conclusion: Shuiludihuang capsule can regulate glucose and fat metabolism, reduce inflammation, reduce Angptl4, Desmin and NF-κB expression levels in renal tissue, improve renal podocyte injury, reduce urinary protein, and delay renal fibrosis and sclerosis. Its mechanism may be related to Angptl4, Desmin and NF-κB pathways.
ABSTRACT
Objective To observe effect and possible mechanism of Tangshen 1st Capsule on diabetic nephropathy rats. Methods Diabetic nephropathy model was established by SD rat ip injected with STZ. Dividing model rats randomly into six groups, 15 rats in model group, 15 rats in benazepril (1.04 g/kg) group, 15 rats in Tangshen 1st Capsule (9 g/kg), 15 rats in Tangshen 1st Capsule (6 g/kg), and 15 rats in Tangshen 1st Capsule (3 g/kg) group; In addition, there were 15 rats designated as normal control group. Rats in normal control group and model group were given corresponding drugs for 8 weeks. After 8 weeks, it was time to observe the blood glucose, blood lipid, cystain c, SREBP-1c, SREBP-2c, urinary albumin, expression of IRS-1, PI3K, and podocin protein levels in renal tissue. Results Compared with model group after treatment, in Tangshen 1st Capsule high-dose group and mid-dose group, blood glucose, blood lipid, cystain C, and urinary microalbumin decreased significantly (P 0.05), in high-dose group, and mid-dose group were statistically significant (P < 0.05). Conclusion Tangshen 1st Capsule have protective effects on diabetic nephropathy rats, and its mechanisms are in part associated with reducing blood glucose and blood lipid, and increasing podocin protein expression.